Juntendo Educational Foundation

Riken Corporation

Saitama Medical University

Other

Yasushi Okazaki

Izumi Sugahara

Masahito Matsumoto

Yoshihide Hayashizaki

Hideo Toyoshima

Tomotaka Yokoo

Chouhei Sakakura

Hisakazu Yamagishi Hisakazu

Igor Kurochkin

Toshiwo Andoh

Christian Schoenbach

Tetsuo Sugahara

A method for producing pancreatic endocrine cells, including introducing (B) or (D) below into cultured somatic cells to transdifferentiate into a population of pancreatic endocrine cells that include insulin-producing beta-cells: (B) a GLIS1 gene or one or more gene products thereof, a Neurogenin3 gene or one or more gene products thereof, and a Pdx1 gene or one or more gene products thereof; and (D) a GLIS1 gene or one or more gene products thereof, a Neurogenin3 gene or one or more gene products thereof, and a MafA gene or one or more gene products thereof. The GLIS1 gene includes the nucleotide sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The population of pancreatic endocrine cells are produced without undergoing an iPS cell stage.

Method for producing pancreatic endocrine cells

A method for producing pancreatic endocrine cells, including introducing (A), (B), (C), or (D) into somatic cells: (A) mutated GLIS1 gene having 85%-sequence-identity to base sequence of SEQ ID NO: 1 or 2 or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, Pdx1 gene or gene product(s) thereof, and MafA gene or gene product(s) thereof; (B) mutated GLIS1 gene having 85%-sequence-identity to base sequence of SEQ ID NO: 1 or 2 or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, and Pdx1 gene or gene product(s) thereof (C) GLIS1 gene or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, Pdx1 gene or gene product(s) thereof, and MafA gene or gene product(s) thereof and (D) mutated GLIS1 gene having 85%-sequence-identity to base sequence of SEQ ID NO: 1 or 2 or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, and MafA gene or gene product(s) thereof.

Method for producing pancreatic endocrine cells, and transdifferentiation agent

A method for producing pancreatic endocrine cells, the method including

Pancreatic endocrine cells, method for producing same, and transdifferentiation agent

Provided are a new peptide, a vector inserting a DNA that codes said peptide, a transformant obtained by transformation with that vector, and applications of said peptide, vector and transformant. The peptide comprises an amino acid sequence set forth in SEQ ID NO: 1, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to/from the amino acid sequence set forth in SEQ ID NO: 1. This peptide and the vector inserting a DNA that codes this peptide are suitable for use in an agent for promoting the proliferation of pancreatic hormone-producing cells, or a differentiation induction promoter that induces differentiation to pancreatic hormone-producing cells.

Peptide and application thereof

A malignant tumor cell suppressor protein (a) or (b):

Malignant tumor cell suppressor protein, malignant tumor cell suppressor gene, maligant tumor cell suppressive viral vector, and kit using the same

Metastatic cancer cells originating from gastric cancer are detected by a method comprising the step of collecting a biological sample from a subject, the step of detecting the presence of at least either aldehyde dehydrogenase or dopa decarboxylase in the biological sample of the subject, and the step of determining that the possibility of containing metastatic cancer cells originating from the gastric cancer in the sample is high when at least either aldehyde dehydrogenase or dopa decarboxylase is present. By the use of these as markers for metastatic cancer cells originating from gastric cancer, the presence or absence of peritoneal metastasis in a gastric cancer patient can be detected rapidly and reliably, and data important for deciding whether intraperitoneal cancer chemotherapy should be applied is provided.

Method of detecting metastasizing cancer cells originating in stomach cancer

The invention relates to a pharmaceutical composition for treating or diagnosing a disorder associated with production of peroxisome in a cell, comprising a polypeptide which has cysteine protease activity and directly processes peroxisomal enzymes targeted by PTS1 or PTS2 signals. Preferably, the polypeptide is encoded by Tysnd1.

Growing community of inventors

Saitama, Japan

Yasushi Okazaki